An experimental Alzheimer’s drug raises hopes for patients suffering from the condition. The new drug appears to slow down the effects of the degenerative diseases for over a hundred trial patients.
After an eighteen-month period, patients that have received the highest dose of this new drug saw marked improvement in their cognition ability. The antibody presently named BAN2401 seemed to slow down cognitive decline versus the effects of a placebo pill.
Experts in the field certainly welcome this new development. This is especially true considering how experts like Susan Greenfield have seen so many once-promising treatments that just ended up failing repeatedly. This discovery sheds light on a brain disease that is age-related and could actually offer that much-needed hope for patients to finally receive better treatments.
Sufferers of Alzheimer’s disease experience cognitive decline. This is also accompanied by a decline in their physical and behavioral abilities. As of the moment, the disease does not have a cure. Still, there are many caveats about this new study. This is especially true considering how it was led by company scientists instead of academic researchers. In addition, it has yet to be reviewed by outside experts too.
There is the fact that the drug was not able to meet its target of 856 participants. This is why; it is still considered a flop. Still, company officials from Biogen and Eisai have stated that the 161 people who have received the highest dose of the antibody every two weeks for the whole 18 –month period show to be doing significantly better when compared to 245 individuals who were only given dummy treatments.
Experts have stated that in order for the results to be considered as definitive, there needs to be a larger study that should be conducted. Still, this is a glimmer of success that the scientific community really welcomes especially in light of numerous drug trials that have been done in the past that all just resulted in failure.
Most of the experts are looking at this new development with cautious optimism. A 30% slowing of the degenerative decline is certainly something that people with loved ones who have the disease would want for their loved ones. The drug also seems to have an ability to clear the plaques in the brain too. Brain scans also seem to support the signs that the drug is indeed effective.
Alzheimer’s disease is a progressive disorder in the brain that slowly degenerates thinking skills, memory, and even the ability of an individual to perform simple, every day tasks. It is often considered as the cause of about 60% to 70% of dementia cases. Majority of the people that are diagnosed with the disease are 65 years old and older. The cause for the disease is still relatively unknown. However, those people who have the APOE gene have a higher chance of developing the late-onset of the disease. At present, it still does not have a cure.
Stay up-to-date with the latest developments concerning Alzheimer’s disease and the brain by reading about Susan Greenfield online.